​

Enliven Therapeutics Stock (NASDAQ:ELVN)

ForecastOwnershipFinancialsChart
Enliven Therapeutics by TradingView

Previous Close

$36.11

52W Range

$14.79 - $48.53

50D Avg

$41.33

200D Avg

$27.46

Market Cap

$2.25B

Avg Vol (3M)

$1.13M

Beta

0.40

Div Yield

-

ELVN Company Profile

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

62

IPO Date

Mar 12, 2020

Website

ELVN Performance

ELVN Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-119.66M$-104.55M$-83.53M
Net Income$-103.69M$-89.02M$-71.58M
EBITDA$-119.66M$-104.24M$-83.23M
Basic EPS$-1.83$-1.89$-2.01
Diluted EPS$-1.83$-1.89$-2.01

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
IMTXImmatics N.V.
ATAIAtai Beckley Inc.
RLAYRelay Therapeutics, Inc.
NKTRNektar Therapeutics
SANASana Biotechnology, Inc.
SNDXSyndax Pharmaceuticals, Inc.
ORICORIC Pharmaceuticals, Inc.
PGENPrecigen, Inc.
INBXInhibrx Biosciences, Inc.
DNTHDianthus Therapeutics, Inc.